XOMA Royalty

XOMA · NASDAQ

Price unavailable right now.

No price history for this range.

About XOMA

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees
14
Headquarters
Emeryville, California
Listed
Jun 6, 1986
Sector
Health Care
Industry
Biotechnology
Website
xoma.com

XOMA key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 4 analystsAvg $45.39
Low
$39.39
High
$52.50

XOMA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 580.6% on average.

  1. Q2 FY24: reported $0.84 per share against an estimate of -$0.273
  2. Q3 FY24: reported -$1.59 per share against an estimate of -$0.4454
  3. Q4 FY24: reported -$0.45 per share against an estimate of -$0.3094
  4. Q1 FY25: reported $0.06 per share against an estimate of -$0.3046
  5. Q2 FY25: reported $0.44 per share against an estimate of -$0.2251
  6. Q3 FY25: reported $0.70 per share against an estimate of -$0.0408
  7. Q4 FY25: reported $0.26 per share against an estimate of -$0.1581
  8. Q1 FY26: reported -$0.03 per share against an estimate of $0.1734

XOMA news

  • Press releasePRNewswire

    Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP

  • Press releasePRNewswire

    Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

  • Press releasePRNewswire

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

  • Vandana Singh

    Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Similar companies

Companies in the same industry as XOMA Royalty

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.